Literature DB >> 17568739

Exploitation of structural and regulatory diversity in glutamate racemases.

Tomas Lundqvist1, Stewart L Fisher, Gunther Kern, Rutger H A Folmer, Yafeng Xue, D Trevor Newton, Thomas A Keating, Richard A Alm, Boudewijn L M de Jonge.   

Abstract

Glutamate racemase is an enzyme essential to the bacterial cell wall biosynthesis pathway, and has therefore been considered as a target for antibacterial drug discovery. We characterized the glutamate racemases of several pathogenic bacteria using structural and biochemical approaches. Here we describe three distinct mechanisms of regulation for the family of glutamate racemases: allosteric activation by metabolic precursors, kinetic regulation through substrate inhibition, and D-glutamate recycling using a d-amino acid transaminase. In a search for selective inhibitors, we identified a series of uncompetitive inhibitors specifically targeting Helicobacter pylori glutamate racemase that bind to a cryptic allosteric site, and used these inhibitors to probe the mechanistic and dynamic features of the enzyme. These structural, kinetic and mutational studies provide insight into the physiological regulation of these essential enzymes and provide a basis for designing narrow-spectrum antimicrobial agents.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17568739     DOI: 10.1038/nature05689

Source DB:  PubMed          Journal:  Nature        ISSN: 0028-0836            Impact factor:   49.962


  38 in total

1.  Equilibrium fluctuations of a single folded protein reveal a multitude of potential cryptic allosteric sites.

Authors:  Gregory R Bowman; Phillip L Geissler
Journal:  Proc Natl Acad Sci U S A       Date:  2012-07-02       Impact factor: 11.205

2.  Exploring the chemistry and evolution of the isomerases.

Authors:  Sergio Martínez Cuesta; Syed Asad Rahman; Janet M Thornton
Journal:  Proc Natl Acad Sci U S A       Date:  2016-02-03       Impact factor: 11.205

Review 3.  Nontraditional therapies to treat Helicobacter pylori infection.

Authors:  Morris O Makobongo; Jeremy J Gilbreath; D Scott Merrell
Journal:  J Microbiol       Date:  2014-03-29       Impact factor: 3.422

4.  Pyridodiazepine amines are selective therapeutic agents for helicobacter pylori by suppressing growth through inhibition of glutamate racemase but are predicted to require continuous elevated levels in plasma to achieve clinical efficacy.

Authors:  Boudewijn L M de Jonge; Amy Kutschke; Joseph V Newman; Michael T Rooney; Wei Yang; Christer Cederberg
Journal:  Antimicrob Agents Chemother       Date:  2015-02-02       Impact factor: 5.191

5.  An Atomistic Understanding of Allosteric Inhibition of Glutamate Racemase: a Dampening of Native Activation Dynamics.

Authors:  Katie R Witkin; Nicholas R Vance; Colleen Caldwell; Quinn Li; Liping Yu; M Ashley Spies
Journal:  ChemMedChem       Date:  2020-01-21       Impact factor: 3.466

6.  Discovery of multiple hidden allosteric sites by combining Markov state models and experiments.

Authors:  Gregory R Bowman; Eric R Bolin; Kathryn M Hart; Brendan C Maguire; Susan Marqusee
Journal:  Proc Natl Acad Sci U S A       Date:  2015-02-17       Impact factor: 11.205

7.  Hybrid Steered Molecular Dynamics-Docking: An Efficient Solution to the Problem of Ranking Inhibitor Affinities Against a Flexible Drug Target.

Authors:  Katie L Whalen; Kevin M Chang; M Ashley Spies
Journal:  Mol Inform       Date:  2011-05-16       Impact factor: 3.353

8.  Elucidating the Catalytic Power of Glutamate Racemase by Investigating a Series of Covalent Inhibitors.

Authors:  Nicholas R Vance; Katie R Witkin; Patrick W Rooney; Yalan Li; Marshall Pope; M Ashley Spies
Journal:  ChemMedChem       Date:  2018-11-21       Impact factor: 3.466

9.  Identification of Highly Specific Diversity-Oriented Synthesis-Derived Inhibitors of Clostridium difficile.

Authors:  Jeremy R Duvall; Leanne Bedard; Adel M Naylor-Olsen; Abigail L Manson; Joshua A Bittker; Wenye Sun; Mark E Fitzgerald; Zhenmin He; Maurice D Lee; Jean-Charles Marie; Giovanni Muncipinto; Diane Rush; Deming Xu; Huisheng Xu; Mingliang Zhang; Ashlee M Earl; Michelle A Palmer; Michael A Foley; Joseph P Vacca; Christina A Scherer
Journal:  ACS Infect Dis       Date:  2017-03-07       Impact factor: 5.084

10.  Asymmetric deactivation of HIV-1 gp41 following fusion inhibitor binding.

Authors:  Kristen M Kahle; H Kirby Steger; Michael J Root
Journal:  PLoS Pathog       Date:  2009-11-26       Impact factor: 6.823

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.